{"denoms":[{"counts":[{"groupId":"BG000","value":"26"}],"units":"Participants"}],"groups":[{"description":"All Patients that received oral aurora A kinase inhibitor MLN8237 and bortezomib IV are summarized in this section.\n\nAurora A kinase inhibitor MLN8237: Given orally","id":"BG000","title":"All Patients"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"46","upperLimit":"79","value":"64.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"16"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26"}]}]}],"description":"Previous treatment for this study is defined as any prior therapy given to the patient for treatment of Myeloma.","paramType":"NUMBER","title":"Previous treatment","unitOfMeasure":"participants"}]}